히알루론산 기반 더말 필러 시장 규모, 점유율, 동향 분석 리포트 : 용도별, 제품별, 지역별, 부문별 예측(2024-2030년)

Hyaluronic Acid-based Dermal Fillers Market Size, Share & Trends Analysis Report By Application (Wrinkle Removal, Lip Augmentation, Rhinoplasty), By Product, By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,242,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,627,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,398,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

히알루론산 기반 더말 필러 시장의 성장과 동향 :

Grand View Research, Inc의 최신 리포트에 따르면 세계의 히알루론산 기반 더말 필러 시장 규모는 2030년까지 82억 4,000만 달러에 달할 것으로 예측되며, 2024-2030년의 CAGR은 10.5%로 성장할 것으로 예측되고 있습니다.

저침습적 시술에 대한 수요 증가, 노인 인구 증가, 젊은 피부에 대한 인식과 관심 증가, 기술 발전이 시장 성장을 가속하는 주요 요인입니다.

전 세계에서 고령화 인구가 증가하고 있으며, 2030년까지 전 세계 인구 6명 중 1명이 60세 이상이 될 것이며, 노인 인구는 11억 명에서 14억 명으로 늘어날 것입니다. 미국에서는 2060년까지 인구의 4분의 1이 65세 이상이 될 것으로 추정됩니다. 현재 전 세계 60세 이상 인구의 3분의 2가 중산층이며, 중산층 국가들이 큰 변화를 목격하고 있습니다.

그러나 높은 시장 비용이 시장 기회를 억제하고 있으며, HA 기반 더말 필러는 1ml 주사기 당 600-1,000 달러의 주사기 당 1ml 주사기 당 600-1,000 달러로 제공됩니다. 대부분의 경우 최소 두 개의 주사기가 필요하며, 치료 비용은 미화 1,600-2,000 달러로 상당히 비쌉니다. 높은 제품 비용으로 인해 중저소득 국가의 사람들에게는 어려운 일입니다.

히알루론산 기반 더말 필러 시장 보고서 하이라이트

• 단상 제품 부문은 2023년 54.76%의 가장 큰 매출 점유율로 시장을 점유했습니다.
• 용도별로는 주름 개선 분야가 2023년 29.53%의 최대 매출 점유율로 시장을 주도했습니다. 이는 미용 성형에 대한 지출 증가와 HA 기반 필러를 이용한 주름 개선 기술의 등장에 기인합니다. 주름 개선은 가장 흔한 피부 문제이며, 그 결과 이 부문 수요가 증가하고 있습니다.
• 북미가 2023년 가장 큰 매출 점유율로 시장을 장악했습니다. 예를 들어 2021년 9월에 발표된 캐나다 통계청의 인구 통계에 따르면 캐나다의 60세 이상 인구는 96,88,677명입니다.
• 아시아태평양 시장은 일본, 중국, 한국과 같은 국가의 급속한 경제 성장과 지역내 의료 인프라 개선으로 인해 예측 기간 중 가장 빠른 CAGR로 성장할 것으로 예상됩니다.
• Allergan(AbbVie)은 세계 시장을 선도하는 주요 기업 중 하나입니다. 이는 HA 기반 더말 필러 쥬비덤(Juvederm)의 오랜 시장 입지와 새로운 제품 출시에도 불구하고 높은 제품 성능에 기인합니다. 이 회사는 HA 기반 더말 필러의 강력한 제품 포트폴리오를 보유하고 있으며, 혁신적인 제품을 시장에 출시하는 데 주력하고 있습니다.

목차

제1장 히알루론산 기반 더말 필러 시장 : 조사 방법과 범위

제2장 히알루론산 기반 더말 필러 시장 : 주요 요약

• 시장 전망
• 부문 전망
• 경쟁 인사이트

제3장 히알루론산 기반 더말 필러 시장 : 변수, 동향, 범위

• 시장 계통 전망
• 시장 역학
• 비즈니스 환경 분석 툴
• 정성 분석 : COVID-19가 히알루론산 기반 더말 필러 시장에 미치는 영향

제4장 히알루론산 기반 더말 필러 시장 : 제품 추정·동향 분석

• 히알루론산 기반 더말 필러 시장 : 제품 대시보드
• 히알루론산 기반 더말 필러 시장 : 제품의 변동 분석
• 히알루론산 기반 더말 필러 시장 규모와 예측 및 동향 분석, 제품별, 2018-2030년
• 단상 제품
• 듀플렉스 제품

제5장 히알루론산 기반 더말 필러 시장 : 용도 추정·동향 분석

• 히알루론산 기반 더말 필러 시장 : 용도 대시보드
• 히알루론산 기반 더말 필러 시장 : 용도의 변동 분석
• 히알루론산 기반 더말 필러 시장 규모와 예측 및 동향 분석, 용도별, 2018-2030년
• 주름 제거
• 입술 확대
• 코 성형술
• 기타

제6장 히알루론산 기반 더말 필러 시장 : 지역 추정·동향 분석

• 히알루론산 기반 더말 필러 시장 : 지역 대시보드
• 시장 규모와 예측 동향 분석, 2018-2030년
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제7장 경쟁 구도

• 주요 시장 참여 기업별 최근 동향과 영향 분석
• 기업/경쟁의 분류
• 벤더 구도
  • Key company market share analysis, 2023
  • Allergan;Galderma Laboratories
  • Merz Pharmaceuticals
  • Genzyme Corporation
  • Anika Therapeutics Inc.
  • LG Life Sciences
  • LTD(LG Chem)
  • Bio plus Co. Ltd.
  • Sculpt Luxury
  • Dermal Fillers Ltd.
  • Bioxis Pharmaceutical
  • Sinclair Pharma;Laboratories
  • Vivacy;Bohus Biotech AB

KSA

영문 목차

영문목차

Hyaluronic Acid-based Dermal Fillers Market Growth & Trends:

The global hyaluronic acid-based dermal fillers market size is anticipated to reach at USD 8.24 billion by 2030 and is projected to grow at a CAGR of 10.5% from 2024 to 2030, based on a new report by Grand View Research, Inc. The increasing demand for minimally invasive procedures, growing geriatric population, increasing awareness & concern for younger skin and advancement in technology are key factors driving the market growth.

The global ageing population is increasing. By 2030, 1 in 6 persons globally will be above 60 years old or over with total elder population growing from one 1 to 1.4 billion. In the U.S., it is estimated that one fourth of the people will be above 65 by 2060. Currently the middle-income countries are witnessing huge change with two-thirds of global population over 60 years would be from middle-income countries.

However, the higher cost of market is restraining the market opportunities. The HA-based dermal fillers are available in syringes of 1ml costing USD 600-1000 per syringe. Most of the times a dosage of minimum 2 syringes is required, taking the cost of treatment to USD 1600-2000 which is quite high. The high cost of products makes it difficult for the population of low- medium-income countries.

Hyaluronic Acid-based Dermal Fillers Market Report Highlights:

• The single-phase products segment held the market with the largest revenue share of 54.76% in 2023, owing to the benefits like better effectiveness & offered by these products
• Based on application, the wrinkle removal segment led the market with the largest revenue share of 29.53% in 2023. This can be attributed to the increasing spending on cosmetic procedures and the advent of technology for Wrinkle Removal suing HA-based fillers. Wrinkle Removal is the most common skin problems, resulting higher demand for the segment
• North America dominated the market with the largest revenue share of in 2023. This can be attributed to favorable government policies, a rise in the number of plastic surgery procedures and an growing ageing population in the region For instance, as per the Statistics Canada's population statistics published in September 2021, the total population above 60 years of age in Canada is 96, 88,677
• The Asia Pacific market is expected to grow at the fastest CAGR during the forecast period, owing to the rapid economic growth in nation like Japan, China & South Korea and improvement in healthcare infrastructure in the region
• Allergan (AbbVie), is a one of the major global market leaders. This can be attributed to market presence of Juvederm, a HA based dermal filler by the company for long time and better performance of product despite new products being introduced. The company's has powerful product portfolio of HA based dermal fillers & focuses on introducing innovative products into in market

Table of Contents

Chapter 1 Hyaluronic Acid-based Dermal Fillers Market: Methodology and Scope

• 1.1 Market Segmentation & Scope
  • 1.1.1 Product
  • 1.1.2 Application
  • 1.1.3 Regional Scope
  • 1.1.4 Estimates and Forecast Timeline
• 1.2 Research Methodology
• 1.3 Information Procurement
  • 1.3.1 Purchased Database
  • 1.3.2 GVR's Internal Database
  • 1.3.3 Secondary Sources
  • 1.3.4 Primary Research
  • 1.3.5 Details of Primary Research
• 1.4 Information or Data Analysis
  • 1.4.1 Data Analysis Models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
  • 1.6.1 Commodity Flow Analysis
• 1.7 List of Secondary Sources
• 1.8 List of Abbreviations
• 1.9 Objectives
  • 1.9.1 Objective 1
  • 1.9.2 Objective 2
  • 1.9.3 Objective 3

Chapter 2 Hyaluronic Acid-based Dermal Fillers Market: Executive Summary

• 2.1 Market Outlook
• 2.2 Segment Outlook
  • 2.2.1 Product
  • 2.2.2 Application
  • 2.2.3 Region
• 2.3 Competitive Insights

Chapter 3 Hyaluronic Acid-based Dermal Fillers Market: Variables, Trends & Scope

• 3.1 Market Lineage Outlook
  • 3.1.1 Parent market outlook
• 3.2 Market Dynamics
  • 3.2.1 Market Driver Analysis
    • 3.2.1.1 Growing Aging Population
    • 3.2.1.2 Increasing Awareness and Acceptance of Aesthetic Treatments
    • 3.2.1.3 Technological Advancements
  • 3.2.2 Market Restraint Analysis
  • 3.2.3 Regulatory Contraints
  • 3.2.4 High Cost of Procedures
• 3.3 Business Environment Analysis Tools
  • 3.3.1 Porter's five forces analysis
    • 3.3.1.1 Bargaining power of buyers: Low
    • 3.3.1.2 Bargaining power of suppliers: Moderate
    • 3.3.1.3 Competitive Rivalry: High
    • 3.3.1.4 Threat of new entrants: Moderate
    • 3.3.1.5 Threat of substitutes: Low
  • 3.3.2 SWOT Analysis, by PESTEL
    • 3.3.2.1 Political & legal
    • 3.3.2.2 Economic
    • 3.3.2.3 Technological
• 3.4 Qualitative Analysis: Impact of COVID-19 on Hyaluronic Acid-based Dermal Fillers Market Market

Chapter 4. Hyaluronic Acid-based Dermal Fillers Market: Product Estimates & Trend Analysis

• 4.1. Hyaluronic Acid-based Dermal Fillers Market: Product Dashboard
• 4.2. Hyaluronic Acid-based Dermal Fillers Market: Product Movement Analysis
• 4.3. Hyaluronic Acid-based Dermal Fillers Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Single-Phase Product
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Duplex Product
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Hyaluronic Acid-based Dermal Fillers Market: Application Estimates & Trend Analysis

• 5.1. Hyaluronic Acid-based Dermal Fillers Market: Application Dashboard
• 5.2. Hyaluronic Acid-based Dermal Fillers Market: Application Movement Analysis
• 5.3. Hyaluronic Acid-based Dermal Fillers Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. Wrinkle Removal
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Lip Augmentation
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Rhinoplasty
  • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Hyaluronic Acid-based Dermal Fillers Market: Regional Estimates & Trend Analysis by Country, Type & Therapy

• 6.1. Hyaluronic Acid-based Dermal Fillers Market: Regional Dashboard
• 6.2. Market Size & Forecasts Trend Analysis, 2018 to 2030
• 6.3. North America
  • 6.3.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.3.2. U.S.
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework/ reimbursement structure
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. U.S. market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.3.3. Canada
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Regulatory framework/ reimbursement structure
    • 6.3.3.3. Competitive scenario
    • 6.3.3.4. Canada market estimates and forecast, 2018 - 2030 (USD Million)
• 6.4. Europe
  • 6.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.4.2. UK
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. UK market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.4.3. Germany
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. Germany market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.4.4. France
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Regulatory framework/ reimbursement structure
    • 6.4.4.3. Competitive scenario
    • 6.4.4.4. France market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.4.5. Italy
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Regulatory framework/ reimbursement structure
    • 6.4.5.3. Competitive scenario
    • 6.4.5.4. Italy market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.4.6. Spain
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Regulatory framework/ reimbursement structure
    • 6.4.6.3. Competitive scenario
    • 6.4.6.4. Spain market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Regulatory framework/ reimbursement structure
    • 6.4.7.3. Competitive scenario
    • 6.4.7.4. Sweden market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.4.8. Norway
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Regulatory framework/ reimbursement structure
    • 6.4.8.3. Competitive scenario
    • 6.4.8.4. Norway market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.4.9. Denmark
    • 6.4.9.1. Key country dynamics
    • 6.4.9.2. Regulatory framework/ reimbursement structure
    • 6.4.9.3. Competitive scenario
    • 6.4.9.4. Denmark market estimates and forecast, 2018 - 2030 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. China market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.5.3. Japan
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. Japan market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.5.4. India
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. India market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.5.5. Australia
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. Australia market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.5.6. Thailand
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Thailand market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.5.7. South Korea
    • 6.5.7.1. Key country dynamics
    • 6.5.7.2. Regulatory framework/ reimbursement structure
    • 6.5.7.3. Competitive scenario
    • 6.5.7.4. South Korea market estimates and forecast, 2018 - 2030 (USD Million)
• 6.6. Latin America
  • 6.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.2. Brazil
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Brazil market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.6.3. Mexico
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework/ reimbursement structure
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. Mexico market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.6.4. Argentina
    • 6.6.4.1. Key country dynamics
    • 6.6.4.2. Regulatory framework/ reimbursement structure
    • 6.6.4.3. Competitive scenario
    • 6.6.4.4. Argentina market estimates and forecast, 2018 - 2030 (USD Million)
• 6.7. MEA
  • 6.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.7.3. South Africa
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. South Africa market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.7.4. UAE
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. UAE market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.7.5. Kuwait
    • 6.7.5.1. Key country dynamics
    • 6.7.5.2. Regulatory framework/ reimbursement structure
    • 6.7.5.3. Competitive scenario
    • 6.7.5.4. Kuwait market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. Key company market share analysis, 2023
  • 7.3.2. Allergan; Galderma Laboratories
    • 7.3.2.1. Company overview
    • 7.3.2.2. Financial performance
    • 7.3.2.3. Type benchmarking
    • 7.3.2.4. Strategic initiatives
  • 7.3.3. Merz Pharmaceuticals
    • 7.3.3.1. Company overview
    • 7.3.3.2. Financial performance
    • 7.3.3.3. Type benchmarking
    • 7.3.3.4. Strategic initiatives
  • 7.3.4. Genzyme Corporation
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Type benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Anika Therapeutics Inc.
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Type benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. LG Life Sciences
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Type benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. LTD (LG Chem)
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Type benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. Bio plus Co. Ltd.
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Type benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. Sculpt Luxury
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Type benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. Dermal Fillers Ltd.
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Type benchmarking
    • 7.3.10.4. Strategic initiatives
  • 7.3.11. Bioxis Pharmaceutical
    • 7.3.11.1. Company overview
    • 7.3.11.2. Financial performance
    • 7.3.11.3. Type benchmarking
    • 7.3.11.4. Strategic initiatives
  • 7.3.12. Sinclair Pharma; Laboratories
    • 7.3.12.1. Company overview
    • 7.3.12.2. Financial performance
    • 7.3.12.3. Type benchmarking
    • 7.3.12.4. Strategic initiatives
  • 7.3.13. Vivacy; Bohus Biotech AB
    • 7.3.13.1. Company overview
    • 7.3.13.2. Financial performance
    • 7.3.13.3. Type benchmarking
    • 7.3.13.4. Strategic initiatives

관련자료